Dermatology Search

Dermatology

Dermatology

Home News Diseases Conferences Special Reports Multimedia

VITILIGO

Vitiligo is an acquired, often familial, melanocytopenic disorder that produces focal depigmentation of the skin.
About half of the patients has onset of lesion before the age of 20.
It is a progressive disease wherein spontaneous repigmentation may occur within 6 months.
Precipitating factors include emotional stress, sunburn, chemical exposure, skin trauma, inflammation, irritation or rash that may precede the lesions by 2-3 months.
Lesions are white-colored macules or patches with well-defined borders and otherwise normal skin surface.

Vitiligo Management

Management

Follow Up

Nonsegmental Vitiligo

NSV patients on narrow band UVB therapy should be reassessed on the 3rd & 6th mth of therapy
If still w/ disease progression after 3 mth of narrow band UVB therapy w/ topical steroid/calcineurin inhibitor therapy, consider switching to systemic corticosteroid therapy
- After 3-6 mth, consider surgical interventions if disease is stable but w/o repigmentation, or depigmentation therapy if w/o repigmentation & w/ Koebner phenomenon
- After 9 mth of narrow band UVB treatment, consider surgical interventions if disease is stable but repigmentation stopped

Segmental Vitiligo

Reassess patients on topical steroids & calcineurin inhibitors on the 6th mth of therapy

Product Highlight - RELIZEMA

16 Jun 2021

Furfuryl Palmitate

Expert consensus: Patient profile should guide antihistamine choice in primary care setting

10 Dec 2019

Oral H₁-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.

Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective

01 Nov 2018

The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.